Friday, December 14, 2018
Home Clinical Trial Updates

Clinical Trial Updates

Oxybutynin Improved Quality of Life for Breast Cancer Survivors

Treatment with oxybutynin chloride (Ditropan XL®; Janssen Pharmaceuticals) helped reduce the frequency and intensity of hot flashes for women who could not take hormone replacement, including breast cancer survivors, according to results of a study presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX. the study was funded by the Breast...

Type of Surgery May affect Health Related Quality of Life for Young Breast Cancer Survivors

Results from a study funded by the Agency for Healthcare Research and Quality, Susan G. Komen, the Breast Cancer Research Foundation, and The Pink Agenda and presented at the San Antonio Breast Cancer Symposium (SABCS), held December 4–8, 2018 in San Antonio, TX, confirm that younger breast cancer patients who underwent mastectomy reported lower breast satisfaction and poorer psychosocial...

MEDALIST Trial in Patients with Myelodysplastic Syndromes Shows Statistical Benefit

Data from the pivotal phase III MEDALIST trial (NCT02631070) shows that treatment with luspatercept (ACE-536), an investigational drug for the treatment of patients with myelodysplastic syndromes, resulted in statistically significant increased red blood cell transfusion independence compared to placebo. Based on the these results Celgene and Acceleron Pharma, the developers of the drug, are planning regulatory submissions in the...

The Future of Medicine is Bright: Personalized Medicine, Predictive Analytics and Big Data

Modern medicine is to change dramatically. Over the past 200 years medicine has seen extraordinary developments and advances. From microbiology to the sequencing of the human genome, the advent of CRISPR–Cas genome editing to potentially treat disease and advance drug discovery and development, as well as a better understanding of underlying biology of cancer and hematological disease, and the availability...

Patients Diagnosed with Adenomas may not Receive Colonoscopies in Recommended Time Frame

Results from a recent study presented in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research (AACR) and  funded by grants from the National Cancer Institute (NCI), shows that patients who are diagnosed with adenomas, a possible precursor of colorectal cancer, my not receive subsequent colonoscopies within the recommended time frame. "Adenomas are a...

Australian Kazia Therapeutics Presents ‘Trial in Progress’ Data for Glioblastoma Study

Results for GDC-0084, an investigational drug being being developed by Australian- based and oncology-focused Kazia Therapeutics, were presented during the annual meeting of the Society for Neuro-Oncology (SNO), held in in New Orleans, LA November 16 - 18, 2018. The investigational agent is currently in human trials for the treatment of patients with glioblastoma, the most common and most aggressive...

Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results

Preliminary results from the CAPTIVE / KEYNOTE-192 study (NCT02798406) dose escalation study evaluating a single intratumoral injection of DNX-2401 (tasadenoturev; DNAtrix) followed by standard dosing with pembrolizumab (Keytruda®; Merck Sharp & Dohme Corp/MSD) every three weeks to determine the optimal dose, safety, and efficacy in patients with recurrent glioblastoma, demonstrate that combination of the two agents is well tolerated...

Scientists, Physicians and Patients Collaborate to Improve Treatment of EGFR-Positive Lung Cancer

The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters have announced the launch of a new study to create a novel bank of patient derived xenograft (PDX) models to help researchers better understand why patients living with Epidermal Growth Factor Receptor (EGFR) positive lung cancer develop resistance to treatment over time, or do not respond at...

Isofol Initiates Pivotal Phase III Clinical Trial of Arfolitixorin for Metastatic Colorectal Cancer

Sweden-based Isofol Medical has initiated their pivotal Phase III clinical trial, called the ISO-CC-007 study, for the treatment of first-line (initial) metastatic colorectal cancer (mCRC). Arfolitixorin is a new drug candidate primarily developed to increase the efficacy of the cytotoxic agent 5‑fluorouracil (5-FU) in the treatment of patients with advanced colorectal cancer and as a rescue drug after high-dose methotrexate...

How to Better Utilize the Immune System – Neoadjuvant Therapy to Help Downstage Tumors

It's a question that begs being answered: Can physicians use immunotherapy more effectively? The answer may be a simple 'Yes.' In the treatment of a number of cancers, immunotherapy is already the standard of care and clinical trials are ongoing for many others. This is especially the case in the treatment of patients with late stage disease. A widely used form of...

Related articles